RELIABILITY OF IMMUNORADIOMETRIC ASSAYS FOR SEX-HORMONE BINDING GLOBULIN, ANDROSTENEDIONE, 17-BETA ESTRADIOL AND TUMOR-MARKERS CEA AND CB15.3 TO ASSESS THE BIOLOGICAL RESPONSE OF MEGESTROL-ACETATE TREATMENT INPATIENTS WITH ADVANCED BREAST-CANCER
C. Botti et al., RELIABILITY OF IMMUNORADIOMETRIC ASSAYS FOR SEX-HORMONE BINDING GLOBULIN, ANDROSTENEDIONE, 17-BETA ESTRADIOL AND TUMOR-MARKERS CEA AND CB15.3 TO ASSESS THE BIOLOGICAL RESPONSE OF MEGESTROL-ACETATE TREATMENT INPATIENTS WITH ADVANCED BREAST-CANCER, International journal of oncology, 5(4), 1994, pp. 881-888
This study evaluated the effect of megestrol acetate administration on
the serological assessment of some sex steroid hormones in women with
advanced hormone-sensitive breast cancer. The serum levels of 17-beta
estradiol, androstenedione and sex hormone binding globulin (SHBG) we
re measured by means of radioimmunometric assays, before and during dr
ug administration. A significant suppressive effect on SHBG and andros
tenedione levels in comparison with the baseline values was reached in
100% (40/40) and 51% (20/39) of patients, respectively, after two mon
ths of therapy; by contrast, 17-beta estradiol levels showed an increa
se above the baseline levels in 18 out of 22 patients. These findings
might be explained on the basis of a possible interference in vivo of
megestrol acetate metabolites particularly in the estradiol assay, sin
ce a direct influence of the solubilized megestrol acetate was not obs
erved in vitro. The hormone levels generally did not shaw any relation
ship with the course of the disease, so their serial determinations do
not seem to be useful to assess the clinical status or evaluate respo
nse to therapy. In our group of patients, CEA and CA15.3 serum determi
nations were also carried out to monitor the efficacy of treatment. CE
A and CA15.3 levels reflected the course of the disease in 58.9% (23/3
9) and 65.8% (25/38) of patients, respectively. The two tumor markers
displayed a similar sensitivity in detecting cancer progression (64% C
EA and 63% CA15.3), but CA15.3 seemed to have a better diagnostic valu
e in evaluating the response to therapy and signalling tumor relapse.